Loading clinical trials...
Loading clinical trials...
To provide extended access to Ixabepilone therapy to subjects with metastatic breast cancer who have completed the previous Phase II study (CA163-107)
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
R-Pharm
NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more
NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer
NCT06428396 · Metastatic Breast Cancer
NCT07347600 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
NCT05534438 · Oligometastatic Breast Carcinoma, Breast Cancer, and more
Local Institution
Nagoya, Aichi-ken
Local Institution
Kashiwa-Shi, Chiba
Local Institution
Fukuoka, Fukuoka
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions